Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00550004 · ClinicalTrials.gov registry record · Phase 2
Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine
A Phase 2 study, sponsored by SciClone Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
NCT00550004: Clinical Trial Phase 2 study, sponsored by SciClone Pharmaceuticals.
NCT00550004 is a Phase 2 study that was terminated before completion, run by SciClone Pharmaceuticals. The registered enrollment target is 153 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00550004, a Phase 2 study, was terminated before completion, sponsored by SciClone Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
Study Summary
This will be a Phase II, multicenter, randomized, double blind, placebo controlled, study of six 28-day treatment cycles for patients with locally advanced, unresectable, or metastatic pancreatic cancer. The study will be conducted at approximately 55 sites in the North American, Europe, and South America. Approximately 153 subjects will be enrolled in a randomization (ratio 2:1).
Interventions
- DRUG RP101
- DRUG Gemcitabine (1000 mg/m2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Why NCT00550004 stopped before completion
NCT00550004 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% higher).
The record links to 0 conditions, and to 2 interventions - of which RP101 is the first listed.
NCT00550004 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00550004 about?
NCT00550004 is a clinical study titled "Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine". This will be a Phase II, multicenter, randomized, double blind, placebo controlled, study of six 28-day treatment cycles for patients with locally advanced, unresectable, or metastatic pancreatic cancer. The study will be conducted at approximately 55 sites in the North American, Europe, and South A...
What is the current status of trial NCT00550004?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2007-09. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00550004?
The interventions under investigation include: RP101 (DRUG), Gemcitabine (1000 mg/m2) (DRUG).
Who is sponsoring clinical trial NCT00550004?
This trial is sponsored by SciClone Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00550004's enrollment target sits among peer trials
153 449th of 2000 higher than 1,549 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia